Cargando…

Comparative risk of infections among real-world users of biologics for juvenile idiopathic arthritis: data from the German BIKER registry

To examine whether treatment with interleukin (IL)-1-, IL-6-, tumour necrosis factor α (TNFα)-inhibitors or Abatacept is associated with an increased risk of common infections, infections requiring hospitalization (SAE) or opportunistic infections among real-world juvenile idiopathic arthritis (JIA)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thiele, Franz, Klein, Ariane, Windschall, Daniel, Hospach, Anton, Foeldvari, Ivan, Minden, Kirsten, Weller-Heinemann, Frank, Horneff, Gerd
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Observational Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952348/ https://www.ncbi.nlm.nih.gov/pubmed/33590331 http://dx.doi.org/10.1007/s00296-020-04774-3

Ejemplares similares

Biologic Therapies in Polyarticular Juvenile Idiopathic Arthritis. Comparison of Long‐Term Safety Data from the German BIKER Registry
por: Klein, Ariane, et al.
Publicado: (2019)

Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry
por: Horneff, Gerd, et al.
Publicado: (2017)

Outcome of children with oligoarticular juvenile idiopathic arthritis compared to polyarthritis on methotrexate- data of the German BIKER registry
por: Raab, A., et al.
Publicado: (2021)

Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry
por: Armaroli, Giulia, et al.
Publicado: (2020)

Adherence, helpfulness and barriers to treatment in juvenile idiopathic arthritis – data from a German Inception cohort
por: Kirchner, Sabine, et al.
Publicado: (2023)

Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis
por: Klotsche, Jens, et al.
Publicado: (2021)

Efficacy and Safety of Etanercept Biosimilars Compared With the Originator for Treatment of Juvenile Arthritis: A Prospective Observational Study
por: Thiele, Franz, et al.
Publicado: (2021)

Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab
por: Horneff, Gerd, et al.
Publicado: (2016)

Prevalence and risk factors of depressive symptoms in children and adolescents with juvenile idiopathic arthritis
por: Roemer, Johanna, et al.
Publicado: (2023)

Protocols on classification, monitoring and therapy in children’s rheumatology (PRO-KIND): results of the working group Polyarticular juvenile idiopathic arthritis
por: Horneff, Gerd, et al.
Publicado: (2017)

Vitamin D deficiency is associated with higher disease activity and the risk for uveitis in juvenile idiopathic arthritis - data from a German inception cohort
por: Sengler, Claudia, et al.
Publicado: (2018)

Experiences with IL-1 blockade in systemic juvenile idiopathic arthritis – data from the German AID-registry
por: Lainka, Elke, et al.
Publicado: (2021)

The German version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
por: Holzinger, Dirk, et al.
Publicado: (2018)

Methotrexate in oligoarticular persistent juvenile idiopathic arthritis
por: Horneff, Gerd, et al.
Publicado: (2014)

Safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis
por: Horneff, G, et al.
Publicado: (2015)

Medication burden in young adults with juvenile idiopathic arthritis: data from a multicentre observational study
por: Montag, Laura J, et al.
Publicado: (2022)

Pharmacovigilance in juvenile idiopathic arthritis patients (Pharmachild) treated with biologic agents and/or methotrexate. Consolidated baseline characteristics from Pharmachild and other national registries
por: Swart, Joost, et al.
Publicado: (2014)

The majority of patients with newly diagnosed juvenile idiopathic arthritis achieve a health-related quality of life that is similar to that of healthy peers: results of the German multicenter inception cohort (ICON)
por: Listing, Miriam, et al.
Publicado: (2018)

German evidence- and consensus-based guidelines 2011 for the treatment of juvenile idiopathic arthritis (JIA)
por: Dueckers, Gregor, et al.
Publicado: (2012)

Cervical spine involvement in patients with juvenile idiopathic arthritis - MRI follow-up study
por: Hospach, Toni, et al.
Publicado: (2014)

Efficacy and safety of TNF inhibitors in the treatment of juvenile idiopathic arthritis: a systematic literature review
por: Horneff, Gerd, et al.
Publicado: (2023)

The majority of newly diagnosed patients with juvenile idiopathic arthritis reach an inactive disease state within the first year of specialised care: data from a German inception cohort
por: Sengler, Claudia, et al.
Publicado: (2015)

Open label multicenter study of once weekly Etanercept 0.8 mg/kg in active polyarticular Juvenile idiopathic arthritis (JIA)
por: Horneff, G, et al.
Publicado: (2008)

Similarities in clinical course and outcome between juvenile idiopathic arthritis (JIA)-associated and ANA-positive idiopathic anterior uveitis: data from a population-based nationwide study in Germany
por: Heiligenhaus, Arnd, et al.
Publicado: (2020)

Fluorescence optical imaging and musculoskeletal ultrasonography in juvenile idiopathic polyarticular disease before and during antirheumatic treatment - a multicenter non-interventional diagnostic evaluation
por: Klein, Ariane, et al.
Publicado: (2017)

Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven‐Year Interim Results
por: Brunner, Hermine I., et al.
Publicado: (2020)

Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany
por: Hinze, Claas H., et al.
Publicado: (2018)

A survey of national and multi-national registries and cohort studies in juvenile idiopathic arthritis: challenges and opportunities
por: Beukelman, Timothy, et al.
Publicado: (2017)

Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement
por: Horneff, Gerd, et al.
Publicado: (2012)

Burden of comorbid conditions in children and young people with juvenile idiopathic arthritis: a collaborative analysis of 3 JIA registries
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2021)

Predictors of response to methotrexate in juvenile idiopathic arthritis
por: Albarouni, Mohamed, et al.
Publicado: (2014)

German evidence and consensus based guidelines 2010 for the treatment of juvenile idiopathic arthritis (JIA)
por: Dueckers, G, et al.
Publicado: (2011)

Outlaw biker violence and retaliation
por: Klement, Christian
Publicado: (2019)

Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries
por: Swart, Joost, et al.
Publicado: (2018)

Course of patients with juvenile spondyloarthritis during 4 years of observation, juvenile part of GESPIC
por: Weiß, Anja, et al.
Publicado: (2017)

The Clinical Phenotypes of the Juvenile Idiopathic Inflammatory Myopathies
por: Shah, Mona, et al.
Publicado: (2013)

Oral or Parenteral Methotrexate for the Treatment of Polyarticular Juvenile Idiopathic Arthritis
por: Bakry, Reima, et al.
Publicado: (2022)

Prevalence of autoantibodies in patients with juvenile idiopathic arthritis: results from the German inception cohort ICON-JIA
por: Schulz, Caroline, et al.
Publicado: (2022)

PReS-FINAL-2152: Biomarkers as predictors of early inactive disease in children with juvenile idiopathic arthritis
por: Lavric, M, et al.
Publicado: (2013)

IL-6 blockade in systemic juvenile idiopathic arthritis – achievement of inactive disease and remission (data from the German AID-registry)
por: Bielak, M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0rvrpehjqmef4r40i44v0g2jlg